ライフサイエンスコーパス: nasal polyp

1 the chronic inflammatory response within the nasal polyps.

2 reported based on the presence or absence of nasal polyps.

3 ntagonist may be considered in patients with nasal polyps.

4 rosis, CRS without nasal polyps, or CRS with nasal polyps.

5 9 was reported in patients with recalcitrant nasal polyps.

6 al tissue from non-CRS and CRS subjects with nasal polyps.

7 ssue remodeling and pathogenesis of CRS with nasal polyps.

8 or trait, such as the presence or absence of nasal polyps.

9 adenoidal hypertrophy, septal deviation and nasal polyps.

10 jects and patients with CRS with and without nasal polyps.

11 respiratory mucosal leucocytes isolated from nasal polyps.

12 in ALI cultures from patients with CRS with nasal polyps.

13 uropean Position Paper on Rhinosinusitis and Nasal Polyps.

14 l subjects and CRS patients with and without nasal polyps.

15 re asthma and/or chronic rhinosinusitis with nasal polyps.

16 types: CRS with nasal polyps and CRS without nasal polyps.

17 f Staphylococcus aureus within mast cells in nasal polyps.

18 ated inflammatory responses in patients with nasal polyps.

19 with asthma and chronic rhinosinusitis with nasal polyps.

20 lonotypes are widely shared in patients with nasal polyps.

21 in patients with chronic rhinosinusitis with nasal polyps.

22 Approximately half of patients reported nasal polyps.

23 epithelium, a pattern also observed in human nasal polyps.

24 chic disorders (2.87, 0.89-9.30-borderline), nasal polyps (1.86, 0.88-3.89-borderline), partial/poor

25 uropean Position Paper on Rhinosinusitis and Nasal Polyps 2012 criteria.

26 uropean Position Paper on Rhinosinusitis and Nasal Polyps 2020 criteria were included.

27 Amongst patients suffering from CRS with nasal polyps, a statistically significant reduction in r

28 nasal polyps, and subjects with CRS without nasal polyps across the clusters (likelihood ratio test,

29 gnificant risk factor for the development of nasal polyps after LTx (hazards ratio, 7.2; 95% confiden

30 Nasal polyp ALDH2 protein and nasal EpC ALDH2 transcript

31 [14.5] years; 204 women [33%]) with CRS and nasal polyps/allergic fungal rhinosinusitis (CRSwNPs+).

32 barrier was found in patients with CRS with nasal polyps along with a decreased expression of TJ pro

33 biopsy specimens from patients with CRS with nasal polyps along with an irregular, patchy, and decrea

34 paranasal sinuses, frequently occurring with nasal polyps and allergies.

35 Nasal polyps and asthma might represent a therapeutic ch

36 dverse events (nasopharyngitis, worsening of nasal polyps and asthma, headache, epistaxis, and inject

37 iseases, such as chronic rhinosinusitis with nasal polyps and asthma, show increased nasal Staphyloco

38 rgic disorders, including atopic dermatitis, nasal polyps and asthma, which are characterized by tiss

39 ould be a treatment option for patients with nasal polyps and asthma.

40 d persistence of chronic rhinosinusitis with nasal polyps and asthma.

41 Among patients with nasal polyps and chronic rhinosinusitis, the prevalence

42 dy of allergic and nonallergic patients with nasal polyps and comorbid asthma (n = 24) was conducted.

43 ical efficacy of omalizumab in patients with nasal polyps and comorbid asthma.

44 Imaging nasal polyps and control middle turbinate explants, we f

45 A and can be differentiated into CRS without nasal polyps and CRS with nasal polyps (CRSwNP).

46 Inflammation in both CRS without nasal polyps and CRS with nasal polyps is highly heterog

47 lly divided into 2 main phenotypes: CRS with nasal polyps and CRS without nasal polyps.

48 with later-onset, mostly severe asthma with nasal polyps and eosinophilia characterized cluster 5.

49 Both OSM and IL-6 are locally produced in nasal polyps and likely promote pathology by negatively

50 However, rhinosinusitis with nasal polyps and olfactory disorder worsened one year af

51 ur patients with chronic rhinosinusitis with nasal polyps and prospectively biobanked polyp homogenat

52 iratory tract using in situ hybridization on nasal polyps and reverse transcriptase PCR of pharyngeal

53 OSM levels in lysates of nasal polyps and uncinate tissue positively correlated w

54 th patients with chronic rhinosinusitis with nasal polyps and/or asthma alone.

55 of patients with chronic rhinosinusitis with nasal polyps and/or asthma.

56 opic dermatitis, chronic rhinosinusitis with nasal polyps, and asthma.

57 CRS) with nasal polyps (CRSwNP), CRS without nasal polyps, and controls without CRS.

58 neous urticaria, chronic rhinosinusitis with nasal polyps, and food allergy.

59 evere airway hyperresponsiveness, more often nasal polyps, and higher levels of blood neutrophils as

60 inflammatory condition that combines asthma, nasal polyps, and hypersensitivity to NSAIDs.

61 s and is now approved for asthma, urticaria, nasal polyps, and most recently, IgE-mediated food aller

62 patients with chronic rhinosinusitis without nasal polyps, and patients with chronic sinusitis with n

63 Charts with search terms for asthma, nasal polyps, and record of respiratory (cohort A) or un

64 ency of controls, and subjects with CRS with nasal polyps, and subjects with CRS without nasal polyps

65 inflammation is controlled in patients with nasal polyps are not well understood.

66 ided into 2 major subgroups based on whether nasal polyps are present or absent.

67 ream drivers of local antibody production in nasal polyps are undetermined.

68 have been long recognized, with and without nasal polyps, are each now known to be heterogeneous, ba

69 Using organ-cultured nasal polyps as a surrogate tissue for human bronchial m

70 th a higher prevalence of rhinosinusitis and nasal polyps as well as eosinophilia and Aspergillus sen

71 ession of the alarmin-like cytokine IL-33 in nasal polyps, as compared with polyps from aspirin-toler

72 linical triad of chronic rhinosinusitis with nasal polyps, asthma, and a hypersensitivity to nonstero

73 linical triad of chronic rhinosinusitis with nasal polyps, asthma, and an intolerance to medications

74 enotypes based on the presence or absence of nasal polyps belies the underlying intricate immunopatho

75 Covalent dimer LTC(4)S was observed in nasal polyp biopsies, indicating that dimerization and i

76 nic hyperplastic eosinophilic sinusitis with nasal polyps, blood eosinophilia, and increased concentr

77 red with mometasone alone reduced endoscopic nasal polyp burden after 16 weeks.

78 rol middle turbinate explants, we found that nasal polyps, but not turbinates, exhibit apical calcium

79 pithelial cells and cells derived from human nasal polyps, but these reagents did not affect CaMK II-

80 ave been associated with disease severity in nasal polyps, but upstream drivers of local antibody pro

81 ally induced IgG antibodies in patients with nasal polyps can inhibit an IgE-mediated proallergic res

82 type 2 immune reactions representing >80% of nasal polyp cases in Europe and the United States.

83 ction of IL-10, but not IL-5 or IFN-gamma by nasal polyp cell suspensions.

84 en-specific IL-5 and IFN-gamma production by nasal polyp cells.

85 -phosphodiesterase inhibitors in transformed nasal polyp (CF-T43) cells homozygous for the deltaF508

86 e for SAgs in respiratory disorders, such as nasal polyps, chronic obstructive pulmonary disease, chr

87 as observed in tissue from CRS subjects with nasal polyps compared to control tissue.

88 MMP3 and MMP7 observed in CRS subjects with nasal polyps compared to CRS subjects without polyps.

89 sinus epithelial tissue of CRS patients with nasal polyps compared with healthy subjects (P = 0.01).

90 and protein levels were highly increased in nasal polyps compared with those seen in control uncinat

91 rum from 80 patients (20 each of CRS without nasal polyps, CRS with nasal polyps, N-ERD, and disease

92 onditions for chronic rhinosinusitis without nasal polyps (CRSsNP) and chronic rhinosinusitis with na

93 Chronic rhinosinusitis (CRS) without nasal polyps (CRSsNP) and CRS with nasal polyps (CRSwNP)

94 patients with chronic rhinosinusitis without nasal polyps (CRSsNP) in comparison with normal subjects

95 Chronic rhinosinusitis (CRS) without nasal polyps (CRSsNP) is a common disease that is charac

96 (CRS) with nasal polyps (CRSwNP) or without nasal polyps (CRSsNP), allergic rhinitis (AR) and contro

97 healthy patients, patients with CRS without nasal polyps (CRSsNP), and patients with CRS with nasal

98 patients with chronic rhinosinusitis without nasal polyps (CRSsNP), chronic rhinosinusitis with nasal

99 RS with nasal polyps (CRSwNP) or CRS without nasal polyps (CRSsNP), or with allergic rhinitis (AR), a

100 f CRS with nasal polyps (CRSwNP) and without nasal polyps (CRSsNP).

101 Subjects in control (n = 29), CRS without nasal polyps (CRSsNP, n = 86), and CRS with nasal polyps

102 nd those with chronic rhinosinusitis without nasal polyps (CRSsNP; P < .01).

103 51.8 [15.3] years; 259 women [53%]) without nasal polyps (CRSsNPs), and 685 participants (47.2%; mea

104 ence of FLCs in CRS patients with or without nasal polyps (CRSw/sNP) was investigated and the effect

105 es from non-AFRS chronic rhinosinusitis with nasal polyp (CRSwNP) patients, the antimicrobial peptide

106 is (AD), asthma, chronic rhinosinusitis with nasal polyps (CRSwNP) and eosinophilic esophagitis (EoE)

107 of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and over half of patients with ast

108 of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) and those with chronic rhinosinusi

109 vided into two distinct phenotypes, CRS with nasal polyps (CRSwNP) and without (CRSsNP).

110 in 5 years after a new diagnosis of CRS with nasal polyps (CRSwNP) and without nasal polyps (CRSsNP).

111 ) without nasal polyps (CRSsNP) and CRS with nasal polyps (CRSwNP) are associated with Th1 and Th2 cy

112 otype (SAEP) and chronic rhinosinusitis with nasal polyps (CRSwNP) are predominantly type 2-driven di

113 of patients with chronic rhinosinusitis with nasal polyps (CRSwNP) are resistant to oral corticostero

114 Chronic rhinosinusitis with nasal polyps (CRSwNP) associated with type 2 inflammatio

115 polyps (CRSsNP), and patients with CRS with nasal polyps (CRSwNP) before surgery.

116 Chronic rhinosinusitis with nasal polyps (CRSwNP) can be a severe and debilitating d

117 Chronic rhinosinusitis with nasal polyps (CRSwNP) causes nasal obstruction and olfac

118 om patients with chronic rhinosinusitis with nasal polyps (CRSwNP) contain increased levels of autore

119 in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) following endoscopic sinus surgery

120 Patients with chronic rhinosinusitis with nasal polyps (CRSwNP) generally have a high symptom burd

121 Chronic rhinosinusitis with nasal polyps (CRSwNP) is a chronic inflammatory conditio

122 Chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP) is a chronic inflammatory disease

123 Chronic rhinosinusitis with nasal polyps (CRSwNP) is a complex inflammatory conditio

124 Chronic rhinosinusitis with nasal polyps (CRSwNP) is a predominantly type 2-mediated

125 Chronic rhinosinusitis with nasal polyps (CRSwNP) is a prevalent chronic inflammator

126 Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease o

127 h diffuse type 2 chronic rhinosinusitis with nasal polyps (CRSwNP) is altered compared to healthy ind

128 Chronic rhinosinusitis with nasal polyps (CRSwNP) is associated with asthma, particu

129 Chronic rhinosinusitis with nasal polyps (CRSwNP) is associated with T(H)2-dominant

130 Chronic rhinosinusitis with nasal polyps (CRSwNP) is associated with TH2-dominant in

131 Chronic rhinosinusitis with nasal polyps (CRSwNP) is characterized by IgE hyperprodu

132 Although chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP) is characterized by T(H)2 inflamma

133 Although chronic rhinosinusitis with nasal polyps (CRSwNP) is characterized by Th2 inflammati

134 Chronic rhinosinusitis with nasal polyps (CRSwNP) is characterized by type 2 (T2) in

135 Chronic rhinosinusitis with nasal polyps (CRSwNP) is characterized by type 2 inflamm

136 Chronic rhinosinusitis with nasal polyps (CRSwNP) is generally associated with sever

137 Chronic rhinosinusitis with nasal polyps (CRSwNP) is often characterized by local pr

138 Chronic rhinosinusitis with nasal polyps (CRSwNP) is one of the most common chronic

139 -L1 and PD-L2 in chronic rhinosinusitis with nasal polyps (CRSwNP) is poorly studied.

140 Chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP) is well characterized by type 2 (T

141 ents with severe chronic rhinosinusitis with nasal polyps (CRSwNP) often require repeat sinus surgery

142 nonasal biopsies from patients with CRS with nasal polyps (CRSwNP) or CRS without nasal polyps (CRSsN

143 ients with chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP) or without nasal polyps (CRSsNP),

144 ILC2s were significantly enriched in nasal polyps (CRSwNP) patients.

145 Chronic rhinosinusitis with nasal polyps (CRSwNP) symptoms are frequently driven by

146 yps (CRSsNP) and chronic rhinosinusitis with nasal polyps (CRSwNP) using real-world clinical practice

147 Global pooled prevalence of CRS and CRS with nasal polyps (CRSwNP) was found to be 8.71% (95% CI, 6.6

148 s) obtained from chronic rhinosinusitis with nasal polyps (CRSwNP) when differentiated in an air-liqu

149 of treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) with dupilumab.

150 rized by asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), and an intolerance of medications

151 polyps (CRSsNP), chronic rhinosinusitis with nasal polyps (CRSwNP), and aspirin-exacerbated respirato

152 uding asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), and is associated with an unfavor

153 by the triad of chronic rhinosinusitis with nasal polyps (CRSwNP), asthma, and intolerance to cycloo

154 the diagnosis of chronic rhinosinusitis with nasal polyps (CRSwNP), but also for monitoring the respo

155 with AERD, chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP), CRS without nasal polyps, and con

156 orithm for chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP), patients suffering from severe un

157 tinct subtype of chronic rhinosinusitis with nasal polyps (CRSwNP).

158 ps, and patients with chronic sinusitis with nasal polyps (CRSwNP).

159 re, uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP).

160 esponsiveness of chronic rhinosinusitis with nasal polyps (CRSwNP).

161 ma, and/or chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP).

162 y diffuse type 2 chronic rhinosinusitis with nasal polyps (CRSwNP).

163 in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

164 in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

165 d into CRS without nasal polyps and CRS with nasal polyps (CRSwNP).

166 in patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

167 gic rhinitis and chronic rhinosinusitis with nasal polyps (CRSwNP); however, their role in promoting

168 sion in sinus tissues from CRS patients with nasal polyps demonstrated a potential role for IL-32 in

169 In subgroup analysis, CRS with and without nasal polyps demonstrated a significant association with

170 Eosinophilic CRS with nasal polyps (ECRSwNP) is a subtype of CRS characterized

171 nasal polyps (CRSsNP, n = 86), and CRS with nasal polyps (eosinophilic NP: ENP, n = 81; non-eosinoph

172 Primary cultures of nasal polyp epithelia from CF patients (delta F508 homoz

173 he European guidelines on rhinosinusitis and nasal polyps (EPOS 2012), CT is used as the main imaging

174 uropean Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) together with sinonasal opacificatio

175 immunopathogenesis of subjects with CRS and nasal polyps experiencing exacerbation.

176 Mast cells sorted from nasal polyps expressed PGD2 synthase (hematopoietic PGD2

177 opic dermatitis, chronic rhinosinusitis with nasal polyps, food allergies and eosinophilic esophagiti

178 inct basal cell trajectory was implicated in nasal polyp formation.

179 leaved active form of TSLP were increased in nasal polyps from patients with AERD relative to those i

180 s of control subjects (NM-C, n = 8) and from nasal polyps from patients with aspirin-exacerbated resp

181 Here we report that nasal polyps from rs16969968 non-smoking carriers exhibi

182 Nasal polyps from subjects with AERD contained many extr

183 erties of local antibody-expressing cells in nasal polyps from subjects with AERD.

184 Primary cells isolated from CF nasal polyps gave similar results.

185 a, endotypes for chronic rhinosinusitis with nasal polyps have been established, with type 2 immune r

186 Nasal polyp homogenates were collected from patients wit

187 IgE-containing nasal polyp homogenates with or without IgG depletion we

188 itating local antibody production and severe nasal polyps in AERD.

189 a severe form of chronic rhinosinusitis with nasal polyps in which nearly all patients express anti-S

190 Chronic rhinosinusitis (CRS) with nasal polyps is a common chronic condition.

191 Chronic rhinosinusitis with nasal polyps is associated with local immunoglobulin hyp

192 Chronic rhinosinusitis with nasal polyps is characterized by TH2-biased eosinophilic

193 Chronic rhinosinusitis with nasal polyps is frequently managed with endoscopic sinus

194 n both CRS without nasal polyps and CRS with nasal polyps is highly heterogeneous, and the frequency

195 terotoxin (superantigen)-specific IgE in the nasal polyp mucosa.

196 om patients with chronic rhinosinusitis with nasal polyps (n = 7) and patients without CRS (n = 5).

197 ps (n=410) or chronic rhinosinusitis without nasal polyps (n=104), were recruited and randomly assign

198 65%] male), with chronic rhinosinusitis with nasal polyps (n=410) or chronic rhinosinusitis without n

199 0 each of CRS without nasal polyps, CRS with nasal polyps, N-ERD, and disease controls) were subjecte

200 ed to compare the transcriptional profile of nasal polyp (NP) cells from patients with AERD and patie

201 Edema represents a key feature of nasal polyp (NP) disease.

202 ucin 4 (MUC4)-tethered mucin is expressed in nasal polyp (NP) epithelial cells and upregulated under

203 s, in their polyp tissue; in addition, their nasal polyp (NP) IgE levels are correlated with disease

204 subjects (P=0.06), and epithelial cells from nasal polyp (NP) tissue (P < 0.05).

205 marker elastase was selectively elevated in nasal polyp (NP) tissue, whereas eosinophilic cationic p

206 ects (n = 12), subjects with CRS but without nasal polyps (NP) (CRSsNP, n = 12) and with CRS with NP

207 Chronic rhinosinusitis with nasal polyps (NP) and allergic rhinitis (AR) is characte

208 est that neutrophils are also elevated in T2 nasal polyps (NP) and that elevated neutrophils display

209 were purified with protein A/G columns from nasal polyps (NP), matching patient serum, and control s

210 ma proteins is a prominent characteristic of nasal polyps (NP).

211 inflammation in nasal epithelial cells from nasal polyps (NP).

212 tissues including inferior turbinate and/or nasal polyps (NPs) and peripheral blood were collected f

213 Nasal polyps (NPs) are characterized by intense edema or

214 the PLUNC family were profoundly reduced in nasal polyps (NPs) compared to uncinate tissue from cont

215 Nasal polyps (NPs) from patients with CRS had increased

216 Tryptase mRNA was significantly increased in nasal polyps (NPs) from patients with CRSwNP (P< .001) c

217 t oncostatin M (OSM) levels are increased in nasal polyps (NPs) of patients with chronic rhinosinusit

218 LP) is known to be elevated and truncated in nasal polyps (NPs) of patients with chronic rhinosinusit

219 LP) is known to be elevated and truncated in nasal polyps (NPs) of patients with chronic rhinosinusit

220 ncreased TSLP mRNA levels have been found in nasal polyps (NPs), expression of TSLP protein and its f

221 r, the presence of DCs in CRS, especially in nasal polyps (NPs), has not been extensively studied.

222 chronic rhinosinusitis (CRS) with or without nasal polyps (NPs), NPs, or eczema/atopic dermatitis.

223 A subset of CRS patients develop nasal polyps (NPs), which are characterized by type 2 in

224 rast to chronic rhinosinusitis (CRS) without nasal polyps (NPs).

225 sitis is common and sometimes complicated by nasal polyps (NPs).

226 isolate single SAE-specific B cells from the nasal polyps of 3 patients with aspirin-exacerbated resp

227 inferior turbinates, middle turbinates, and nasal polyps of CRSwNP patients, we identify two IL-1 si

228 15-oxo-ETE was overproduced in the nasal polyps of patients with nonsteroidal anti-inflamma

229 Adult patients with nasal polyps often have comorbid asthma, adding to the s

230 m induced sputum or supernatants of cultured nasal polyp or turbinate tissues of N-ERD patients or he

231 groups based on underlying disease (asthma, nasal polyps or chronic rhinosinusitis, or both), as wel

232 opic dermatitis, chronic rhinosinusitis with nasal polyps, or chronic spontaneous urticaria should co

233 n patients with cystic fibrosis, CRS without nasal polyps, or CRS with nasal polyps.

234 The current serum-free nasal polyp organ culture model allows physiologically a

235 ptoms compared with placebo in patients with nasal polyps (P < .01).

236 Of interest, type 2-high nasal polyp patients treated with IgE-blocking omalizuma

237 was measured in serum and nasal secretion of nasal polyp patients treated with methylprednisolone, do

238 ically observed features such as presence of nasal polyps, presence of comorbid or systemic diseases,

239 In patients with chronic rhinosinusitis with nasal polyps, primary human sinonasal epithelial cell (H

240 30% of B cells, plasma cells, and T cells in nasal polyps re-express both RAG1 and RAG2, required for

241 Subjects with AERD whose nasal polyps recurred rapidly had higher IgE levels than

242 e dose of aspirin desensitization to prevent nasal polyp recurrence on the one hand and to minimize a

243 higher IgE levels are associated with faster nasal polyp regrowth.

244 ose of 100 mg daily has a positive impact on nasal polyp relapse and seems to be a safe and suitable

245 After 36 months, nasal polyp relapse was less frequent (P = 0.0785) and t

246 ort-Form Health Survey (SF-36) for HRQoL and nasal polyp-related healthcare resource use questionnair

247 The exact cause of nasal polyps remains unknown.

248 included change from baseline to week 24 in Nasal Polyp Score (NPS) and Nasal Congestion Score.

249 ovement from baseline of at least 1 point in Nasal Polyp Score (NPS), nasal congestion (NC) score, an

250 nts were changes from baseline to week 24 in nasal polyp score (NPS), nasal congestion or obstruction

251 At 24 months, median nasal polyp score (NPS), nasal obstruction visual analog

252 Most baseline characteristics, including Nasal Polyp Score (NPS), Sino-Nasal Outcome Test-22 (SNO

253 Change in endoscopic nasal polyp score (range, 0-8; higher scores indicate wo

254 At baseline, C2 patients had higher mean Nasal Polyp Score and higher type 2 biomarker levels tha

255 T2 inflammation in nasal polyposis, reduces nasal polyp score and improves symptoms.

256 based on a composite end point of endoscopic nasal polyp score and nasal polyposis severity visual an

257 Mean (SE) change from baseline in nasal polyp score at week 16 was 0.20 (0.224) for fevipi

258 utcomeTest-20 (SNOT-20) scores and the total nasal polyp score improved significantly (p < .05) on Da

259 The least squares (LS) mean change in nasal polyp score was -0.3 (95% CI, -1.0 to 0.4) with pl

260 sal polyposis severity VAS score, endoscopic nasal polyp score, all individual VAS symptom scores, an

261 sal polyposis severity VAS score, endoscopic nasal polyp score, improvement in individual VAS symptom

262 Nasal polyp score, Sinonasal Outcome Test 22 score, visu

263 nstrated clinically relevant improvements in nasal polyp score, symptom score, and quality-of-life sc

264 placebo in the coprimary endpoints of total nasal polyps score (treatment difference: ANCHOR-1, -0.7

265 y controlled CRSwNP, an endoscopic bilateral nasal polyps score of 5 or more, previous surgery for CR

266 ab had significant improvements in the total nasal-polyp score (mean difference vs. placebo, -2.07; 9

267 Nasal Polyp Scores (NPS) decreased (5.3 +/- 1.8 to 0.7 +

268 ast to patient-reported outcomes, endoscopic nasal polyp scoring by independent blinded readers is an

269 monstrated omalizumab's efficacy in reducing nasal polyp size, improving symptom scores, and enhancin

270 to intranasal corticosteroids did not change nasal polyp size, radiographic scores, symptoms, or dise

271 ved a statistically significant reduction in nasal polyp size, sinus occupancy, symptoms and improved

272 Nasal polyp specimens from patients with AERD and chroni

273 been described in patients with recalcitrant nasal polyps, suggesting a link to persistent infection.

274 erity), and the first decision to treat with nasal-polyp surgery or use of systemic glucocorticoid th

275 type-2 dominant chronic rhinosinusitis with nasal polyps (T2-CRSwNP).

276 Nineteen patients had nasal polyps that were resistant to oral corticosteroids

277 essing TH2 effector cells were identified in nasal polyp tissue but not the healthy nasal mucosa or p

278 munoassay techniques in nasal secretions and nasal polyp tissue homogenates of CRSwNP patients receiv

279 unction of 14-3-3zeta were assessed in human nasal polyp tissue MCs.

280 minated inflammatory signature is typical in nasal polyp tissue of European patients with nasal polyp

281 In nasal polyp tissue of type 2-low patients, a large infil

282 Local IgE production in nasal polyp tissue plays a key role in the T2 inflammato

283 Nasal polyp tissue was harvested from 24 patients sensit

284 The expression of FLCs in nasal polyp tissue was investigated using immunohistoche

285 alveolar lavage fluid, lung tissue, or human nasal polyp tissue were analyzed by means of Western blo

286 onfirmed the increased FLC concentrations in nasal polyp tissue.

287 ithelial cells from control nasal tissue and nasal polyp tissue.

288 nt also decreased type 2 biomarker levels in nasal polyp tissues at Week 16 vs baseline for eosinophi

289 lammatory biomarkers in nasal secretions and nasal polyp tissues of patients with CRSwNP in a randomi

290 human bronchial epithelial cells (NHBEs) and nasal polyp tissues.

291 ting eosinophils exhibited EETs in patients' nasal polyp tissues.

292 The capacity of IgG in nasal polyps to limit IgE-mediated inflammation is based

293 Whole nasal polyp TSLP mRNA expression correlated strongly wit

294 Surgery for nasal polyps was indicated in significantly fewer patien

295 erall population, patients with a history of nasal polyps were also more likely to achieve remission

296 to severe bronchial hyperresponsiveness and nasal polyps were independent predictors of asthma persi

297 hospholipase A2, and LT enzymes in NHBEs and nasal polyps were refractory to corticosteroids.

298 Immunohistochemistry on human nasal polyp with antieotaxin mAbs showed that certain le

299 trated clinical efficacy in the treatment of nasal polyps with comorbid asthma, supporting the import

300 aria, asthma and chronic rhinosinusitis with nasal polyps - with a high need for targeted therapies.